drugset / Trial / NCT04272801
Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer
Phase 2
Active not recruiting
84 enrolled
Shayna Showalter, MD
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective multisite exploratory study for women ≥ 65 years of age with early stage estrogen receptor positive (ER+) breast cancer. These individuals will be treated with 3 months of pre-operative endocrine therapy (pre-ET) with assessment of tolerance to the endocrine therapy by patient reported outcome (PRO) measures (patient surveys).
Timeline
- Start
- 2020-04-07
- Primary completion
- 2024-06-05
- Completion
- 2026-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | — | — |
| Subject | Exemestane | Small molecule | — | — |
| Subject | Letrozole | Other / unclassified | — | — |
| Subject | Tamoxifen | Small molecule | — | — |